HR7895

The PBM Kickback Prohibition Act, HR7895, directly prohibits rebates and other forms of compensation PBMs receive from pharmaceutical manufacturers. This bill fundamentally alters the PBM business model, which relies heavily on these payments. The immediate impact is a reduction in PBM revenue streams, forcing a re-evaluation of their pricing and service offerings. This is not a 'potential' change; it is a direct prohibition that, if enacted, eliminates a significant portion of PBM income. The money trail shifts from PBMs retaining rebates to either lower drug costs for consumers or increased net revenue for pharmaceutical manufacturers. There is no direct appropriation of funds in this bill; instead, it reallocates value within the pharmaceutical supply chain. PBMs like CVS Health ($CVS) through Caremark, Cigna ($CI) through Express Scripts, and UnitedHealth Group ($UNH) through OptumRx derive substantial profits from these rebates. Walgreens Boots Alliance ($WBA) also operates a PBM, Ascent Health Services, which would be impacted. Pharmaceutical manufacturers, including Pfizer ($PFE), Merck ($MRK), and Eli Lilly ($LLY), stand to gain pricing power or see less pressure to offer large rebates, potentially increasing their net drug prices. Historically, efforts to regulate PBM practices have been ongoing. While a direct prohibition on all rebates has not passed at the federal level, increased scrutiny and state-level actions have occurred. For example, in 2017-2018, several states passed legislation aimed at increasing PBM transparency or regulating their practices, leading to minor stock volatility for PBM-heavy companies but no systemic market shift due to the fragmented nature of state laws. This federal bill represents a much broader and more impactful legislative action. The closest historical parallel is the ongoing debate around drug pricing reform, which consistently pressures PBMs and pharmaceutical companies. When the Centers for Medicare & Medicaid Services (CMS) proposed a rule in 2019 to eliminate rebates in Medicare Part D, PBM stocks like $CVS and $UNH saw immediate declines, with $CVS dropping over 5% on the day of the announcement, reflecting market sensitivity to rebate elimination. Specific losers include major PBM operators: CVS Health ($CVS), Cigna ($CI), Elevance Health ($ELV) through CarelonRx, and UnitedHealth Group ($UNH) through OptumRx. These companies face direct revenue erosion. Walgreens Boots Alliance ($WBA) also operates a PBM and will be negatively impacted. Pharmaceutical manufacturers such as Pfizer ($PFE), Merck ($MRK), and Eli Lilly ($LLY) are positioned as potential beneficiaries, as the pressure to offer large rebates diminishes, potentially improving their net drug prices. The bill's referral to the House Committee on Education and Workforce, with Rep. Allen (R-GA) as a sponsor, indicates a focus on employer-sponsored health plans and consumer costs. Rep. Allen's sponsorship, as a Republican, suggests bipartisan interest in PBM reform, increasing legislative momentum. Next steps involve committee hearings and potential markups within the House Committee on Education and Workforce. If it passes committee, it moves to a full House vote. The timeline for passage is uncertain but the referral to committee is a concrete step forward. The bill's impact will materialize upon passage and enactment, which would likely include an implementation period.